AGX51 is primarily known for its role in inhibiting the function of the Id proteins, which are involved in the regulation of cell differentiation and proliferation. This makes it a potential candidate for research in cancer therapy, particularly in targeting cancers where Id proteins are overexpressed, such as certain types of breast cancer and leukemia. By blocking Id proteins, AGX51 can potentially induce cancer cell differentiation and inhibit tumor growth. Additionally, it is being explored for its potential in treating other diseases where cell proliferation is a key factor, such as certain cardiovascular conditions. Its application in these areas is still largely in the experimental and preclinical stages, with ongoing studies to better understand its efficacy and safety profile.